OncoMatch/Clinical Trials/NCT06600698
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA
Is NCT06600698 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies INM176 for prostate cancer.
Treatment: INM176 — This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Required: Stage ANY T STAGE, N0-1
Excluded: Stage DISTANT METASTATIC CANCER
Grade: any Gleason grade (Gleason)
Any T stage, N0-1, M0, any Gleason grade
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: systemic chemotherapy
Subjects who are receiving systemic treatments such as chemotherapy
Cannot have received: androgen deprivation therapy (LHRH agonist, LHRH antagonist, GNRH analogs, antiandrogens)
Subjects who are receiving systemic treatments such as ... androgen deprivation therapy (ADT) or anti-androgen therapy including LHRH agonist, antagonist, GNRH analogs, and antiandrogens
Cannot have received: immunotherapy (checkpoint inhibitor)
Subjects who are receiving systemic treatments such as ... immunotherapy (checkpoint inhibitor)
Cannot have received: investigational agent
Subjects who are receiving systemic treatments such as ... investigational agents
Cannot have received: warfarin (warfarin, coumadin)
Subjects who are taking Warfarin/coumadin.
Lab requirements
Blood counts
Adequate bone marrow function: Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count ≥ 1.0 x 10^9/L. INR, PT, and PTT within normal institutional limits.
Kidney function
Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Chronic kidney disease with calculated GFR <30 mL/min/1.73 m2 using Cockcroft-Gault formula, or measured GFR <30 mL/min/1.73 m2 using a 24-hour urine collection [excluded]
Liver function
Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN)
Cardiac function
History of New York Heart Association Class III or IV heart failure, history of a myocardial infarction within 6 months, or any other cardiac-related problem that would be considered a contraindication for participation in the opinion of the treating physician [excluded]
Subjects must have normal liver and kidney function at baseline: Total bilirubin within normal institutional limits. AST(SGOT)/ALT(SGPT) < 2.5 X upper limit of normal (ULN). Creatinine < 1.5 ULN or creatinine clearance > 50 mL/min/1.73 m2. Adequate bone marrow function: Hgb ≥ 9.0 g/dL, Platelets ≥ 100 x 10^9/L, absolute neutrophil count of ≥ 1.0 x 10^9/L). International Normalized Ratio (INR), Prothrombin Time (PT), and Partial Thromboplastin Time (PTT) within normal institutional limits.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Penn State Cancer Institute · Hershey, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06600698 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic chemotherapy, androgen deprivation therapy, immunotherapy disqualifies patients from enrollment.
What disease stage is eligible?
Stage ANY T STAGE or N0-1 is required.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages